Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Dana Winrow who wrote (1376)	2/3/1998 10:39:00 AM
From: Sigmund	Read Replies (1) \| Respond to of 1894

What was that period of European history...the "no (sic) nothings"? Really!!! Sounds to me like the Sakura deal is off. I think that is fine. There must be a better way.

To: Dana Winrow who wrote (1376)	2/3/1998 1:28:00 PM
From: Cisco	Read Replies (1) \| Respond to of 1894

Dana, Thanks for the response. Cisco

To: Dana Winrow who wrote (1376)	2/3/1998 2:15:00 PM
From: george	Read Replies (1) \| Respond to of 1894

It would be helpful if you would give the reason for Mr. Gombrich's resignation when you feel it is appropriate. George

To: Dana Winrow who wrote (1376)	2/10/1998 10:47:00 AM
From: george	Read Replies (2) \| Respond to of 1894

Dr. Winrow, We have a new president but we have not heard anything about his plans for the company and how he plans to do anything differently than what Mr. Gombrich did. I would like to hear a statement from him and I am sure other stockholders feel the same. I am especially concerned about the delisting issue and a statement about projected sales and earnings for 1988. If you cannot answer now, would you at least post and give a date when we will get these answers? After all, our new president is not new to the company and it should not take him long to assess the situation.....the longer it takes, the worse it seems regarding the future.......anyone on the thread agree or disagree or neutral? George

To: Dana Winrow who wrote (1376)	2/13/1998 9:06:00 AM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

Dana, I have not been able to find the full text of the Blue Cross/Blue Shield Association study by the BC/BS Technology Evaluation Center as of yet. The Wall Street Journal had some interesting points in an article which appeared this morning however. Here are a few excerpts; ...The cost effectiveness study by the Blue Cross/Blue Shield's Technology Evaluation Center examined Cytyc's test and two automated slide-reading systems made by NeoPath Inc. and Neuromedical Systems Inc. The tests are designed to increase the accuracy of cervical-cancer screening. But Dr. Alan Garber, the study's senior author, said all three technologies offered only a "modest" improvement in accuracy compared with conventional tests. Cervical cancer is usually a slow-growing disease, Dr. Garber said, meaning most women who have regular Pap tests "will have their abnormalities detected in time." As a result, he said, the new tests are likely to increase average life expectancy by only a few days for women who are screened frequently. The cost of the new tests might limit access to cervical-cancer screening for poorer women, who are most at risk, Dr. Garber said. The study recommends wider use of traditional Pap tests and improved laboratory standards... Eva Snitkin, analyst at NationsBanc Montgomery Securities, said the study could slow the acceptance of the Cytyc test among insurers, which are resistant to tripling their $500 million annual spending for cervical-cancer screening. But Ms. Snitkin said she doubts insurers that already have accepted the test, including 16 Blue Cross affiliates, will rescind their approvals." Frank